Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)

Shots: Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease that leads to the progressive degeneration of nerve cells in the spinal cord and brain Our Disease of the Month report covers epidemiology, market size, current management strategies, emerging therapeutic options, and the role of patient advocacy groups. Additionally, we highlight the key industry…

ByDipanshu DixitFebruary 25, 2025

VIEWPOINTS

Transcending Epilepsy Care: Jason Lerner from Biohaven in an Enlightening Dialogue Exchange with PharmaShots

Shots: Epilepsy affects around 1.5 million people in the US and 50 million globally. With approximately 40% of epilepsy patients being drug-resistant, there is an urgent need for innovative therapies Today, at PharmaShots we have Dr. Jason Lerner from Biohaven shedding light on BHV-7000, an investigational anti-seizure treatment and selective activator of potassium channels in…

BySaurabh ChaubeyNovember 6, 2024

INSIGHTS+

Disease of the Month – Neuroblastoma

Shots: The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved For the February edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Neuroblastoma, a rare…

BySenior EditorFebruary 13, 2024

INSIGHTS+

Disease of the Month – Glioblastoma

Shots: The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved For the January edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Glioblastoma, the most…

BySenior EditorJanuary 11, 2024

VIEWPOINTS

Gregory Bell, CMO at Attralus Shares Insights from its License Agreement with Ossianix to Use Ossianix’s Brain Shuttle Technology

Shots:Gregory initially spoke about the Attralus licensing agreement with Ossianix’s brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s DiseaseHe also talked about how Ossianix VNAR antibody-based brain shuttle TXP1 will help Attralus to deliver AT-04, its developmental PAR therapeutic candidate,…

BySenior EditorMay 30, 2023

INSIGHTS+

Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)

Shots: To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research To continue the series for the disease of the month, PharmaShots brings this month a summary of the disease Amyotrophic Lateral Sclerosis (ALS), a rare…

ByDipanshu DixitMay 11, 2023

Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)

Transcending Epilepsy Care: Jason Lerner from Biohaven in an Enlightening Dialogue Exchange with PharmaShots

Disease of the Month – Neuroblastoma

Disease of the Month – Glioblastoma

Gregory Bell, CMO at Attralus Shares Insights from its License Agreement with Ossianix to Use Ossianix’s Brain Shuttle Technology

Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)

Contact US

OUR INFORMATION

FOLLW US

Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)

Transcending Epilepsy Care: Jason Lerner from Biohaven in an Enlightening Dialogue Exchange with PharmaShots

Disease of the Month – Neuroblastoma

Disease of the Month – Glioblastoma

Gregory Bell, CMO at Attralus Shares Insights from its License Agreement with Ossianix to Use Ossianix’s Brain Shuttle Technology

Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)

FOLLW US

Sign Up to Our Newsletter